SE0101093D0 - Novel compound for treatment of allergy and asthma - Google Patents

Novel compound for treatment of allergy and asthma

Info

Publication number
SE0101093D0
SE0101093D0 SE0101093A SE0101093A SE0101093D0 SE 0101093 D0 SE0101093 D0 SE 0101093D0 SE 0101093 A SE0101093 A SE 0101093A SE 0101093 A SE0101093 A SE 0101093A SE 0101093 D0 SE0101093 D0 SE 0101093D0
Authority
SE
Sweden
Prior art keywords
allergy
asthma
treatment
novel compound
ige
Prior art date
Application number
SE0101093A
Other languages
English (en)
Swedish (sv)
Inventor
Sylvia Laffer
Erik Hogbom
Kenneth H Roux
Jonas Adrianson
Wolfgang R Sperr
Peter Valent
Dietrich Kraft
Hans Groenlund
Rudolf Valenta
Original Assignee
Pharmacia Diagnostics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Diagnostics Ab filed Critical Pharmacia Diagnostics Ab
Priority to SE0101093A priority Critical patent/SE0101093D0/xx
Publication of SE0101093D0 publication Critical patent/SE0101093D0/xx
Priority to EP02720698A priority patent/EP1373322A1/en
Priority to AU2002251624A priority patent/AU2002251624B8/en
Priority to CA2441048A priority patent/CA2441048C/en
Priority to JP2002577880A priority patent/JP2005500992A/ja
Priority to PCT/SE2002/000636 priority patent/WO2002079257A1/en
Priority to US10/108,301 priority patent/US6986889B2/en
Priority to US12/757,821 priority patent/USRE42324E1/en
Priority to JP2013166370A priority patent/JP2014012683A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE0101093A 2001-03-28 2001-03-28 Novel compound for treatment of allergy and asthma SE0101093D0 (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE0101093A SE0101093D0 (sv) 2001-03-28 2001-03-28 Novel compound for treatment of allergy and asthma
EP02720698A EP1373322A1 (en) 2001-03-28 2002-03-28 Novel compound for treatment of allergy and asthma
AU2002251624A AU2002251624B8 (en) 2001-03-28 2002-03-28 Novel compound for treatment of allergy and asthma
CA2441048A CA2441048C (en) 2001-03-28 2002-03-28 Novel compound for treatment of allergy and asthma
JP2002577880A JP2005500992A (ja) 2001-03-28 2002-03-28 アレルギーおよび喘息の治療用新規化合物
PCT/SE2002/000636 WO2002079257A1 (en) 2001-03-28 2002-03-28 Novel compound for treatment of allergy and asthma
US10/108,301 US6986889B2 (en) 2001-03-28 2002-03-28 Compound for treatment of allergy and asthma
US12/757,821 USRE42324E1 (en) 2001-03-28 2010-04-09 Compound for treatment of allergy and asthma
JP2013166370A JP2014012683A (ja) 2001-03-28 2013-08-09 アレルギーおよび喘息の治療用新規化合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0101093A SE0101093D0 (sv) 2001-03-28 2001-03-28 Novel compound for treatment of allergy and asthma

Publications (1)

Publication Number Publication Date
SE0101093D0 true SE0101093D0 (sv) 2001-03-28

Family

ID=20283563

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0101093A SE0101093D0 (sv) 2001-03-28 2001-03-28 Novel compound for treatment of allergy and asthma

Country Status (7)

Country Link
US (2) US6986889B2 (enExample)
EP (1) EP1373322A1 (enExample)
JP (2) JP2005500992A (enExample)
AU (1) AU2002251624B8 (enExample)
CA (1) CA2441048C (enExample)
SE (1) SE0101093D0 (enExample)
WO (1) WO2002079257A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884877B2 (en) 2001-10-03 2005-04-26 Florida State University Research Foundation, Inc. Purified linear epitopes from cashew nuts, nucleic acids encoding therefor, and associated methods
CA2624081C (en) * 2005-09-29 2014-09-16 Medimmune, Inc. Method of identifying membrane ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
US10196458B2 (en) 2013-07-26 2019-02-05 The Regents Of The University Of California Anti-immunoglobulin E antibodies and methods of using thereof
JP2025533898A (ja) * 2022-10-07 2025-10-09 アブウィズ バイオ，インコーポレイテッド 抗ｉｇｅ抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3156237B2 (ja) * 1991-12-24 2001-04-16 雪印乳業株式会社 抗ヒトＩｇＥ モノクローナル抗体
US6037453A (en) * 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
WO2000072879A1 (en) 1999-05-26 2000-12-07 Tanox, Inc. TREATING ALLERGIC DISEASES WITH IMMUNOTHERAPY AND IgE ANTAGONISTS

Also Published As

Publication number Publication date
JP2014012683A (ja) 2014-01-23
CA2441048A1 (en) 2002-10-10
CA2441048C (en) 2011-12-13
US6986889B2 (en) 2006-01-17
AU2002251624A2 (en) 2008-05-01
US20030035796A1 (en) 2003-02-20
AU2002251624B8 (en) 2008-10-02
EP1373322A1 (en) 2004-01-02
WO2002079257A1 (en) 2002-10-10
USRE42324E1 (en) 2011-05-03
AU2002251624B2 (en) 2008-09-04
JP2005500992A (ja) 2005-01-13

Similar Documents

Publication Publication Date Title
SE0401601D0 (sv) Protofibril specific antibodies and uses thereof
MXPA00011422A (es) Derivados de bencimidazol como moduladores de ige.
DE60230029D1 (de) Immunisierungstherapie zur behandlung von atherosklerose
ATE504315T1 (de) Methode für die ausarbeitung von cd10-aktivierten prodrug-verbindungen
ATE307592T1 (de) Epiallopregnanolon zur behandlung von krankheiten des cns
AP1744A (en) Inhibitors of factor XA and other serine proteases involved in the coagulation cascade
EA200300873A1 (ru) Новая соль сукцинат o-десметилвенлафаксина
WO2005003171A3 (en) Modified antibody fragments
AT500379A3 (de) Tau-proteine
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
MA31899B1 (fr) Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
ATE517926T1 (de) Antikörper zur hemmung der aktivität von mmp-2 und mmp-9
DK1636561T3 (da) Kombinatorisk proteinbiblioteksscreening ved hjælp af periplasmatisk ekspression
NO20070423L (no) Ny anvendelse av peptidforbindelser for behandling av essensiell tremor og andre tremorsyndromer
ATE373016T1 (de) Induktion von immunologischer toleranz gegen einen therapeutischen antikörper durch varianten des therapeutischen antikörpers
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
NO20033220L (no) Inhibitorer for cruzipain og andre cysteinproteaser
EA200401081A1 (ru) Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro
DE50208918D1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
EP1411962A4 (en) TREATMENT OF PANCREATIC CANCER WITH A MONOCLONAL ANTIBODY
SE0102716D0 (sv) Novel compounds
SE0302304D0 (sv) Novel compounds
SE0101093D0 (sv) Novel compound for treatment of allergy and asthma
HN2002000366A (es) Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma
HUP0300142A2 (hu) Humán LDL-receptorra specifikus monoklonális ellenanyagok, előállításuk és alkalmazásuk